Oncopeptides is a late-stage pharmaceutical company focused on the development of therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen (also referred to as melphalan flufenamide), an anti-cancer peptide-drug conjugate designed to rapidly deliver an alkylating payload into tumor cells. Melflufen is an investigational drug and has not been approved by the FDA or any other regulatory agency.
Oncopeptides benefits from drawing on the world-class knowledge and experience of its co-workers. In addition to its core team and the standing network of collaborators, Oncopeptides has established further collaborative relationships with leading researchers and institutions in Europe and the US.
About Multiple Myeloma
Multiple myeloma is a cancer of the bone marrow that results in the production of abnormal blood plasma cells.
Approximately three in every 10,000 people are diagnosed with multiple myeloma worldwide each year (1), making it a rare disease. The average age for diagnosis is 70 years of age and there is currently no cure, with most patients dying within five years of their diagnosis.
While patients being treated for multiple myeloma will experience symptom free periods, they will inevitably experience relapses as the disease develops a resistance to the treatments being used. At this point the disease is classified as triple-class refractory multiple myeloma. Once the disease returns, either during treatment or within two months of the patient’s last treatment, the disease is classified as late-stage triple-class refractory multiple myeloma.
Melflufen is in development as a potential treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including: the pivotal phase 2 HORIZON study, the ongoing phase 3 OCEAN study, the phase 1/2 combination ANCHOR study, and the phase 2 BRIDGE study.
Oncopeptides plans to file a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma following the successful data from the HORIZON study. Target submission date to the FDA is H1, 2020. Melflufen is an investigational drug and has not been approved by the FDA or any other regulatory agency.
Visit our Clinical Studies page to learn more about these trials and Oncopeptides’ clinical development efforts. Company announcements and breaking news can be found on the Media page. Additionally, visit our Presentations page to learn more about Oncopeptides’ congress presentations.